Results 91 to 100 of about 109,707 (304)
ABSTRACT Coronary slow flow (SF) and no‐reflow (NR) are clinically significant complications of percutaneous coronary intervention (PCI), particularly in ST‐segment elevation myocardial infarction (STEMI) and saphenous vein graft (SVG) interventions. Angiographically defined as impaired myocardial perfusion despite restored epicardial patency, SF/NR ...
Bharat Khialani +5 more
wiley +1 more source
Metformin is the most widely prescribed antidiabetic drug, yet adherence remains difficult to objectively assess. Using untargeted metabolomics and lipidomics, we analyzed plasma from 637 patients with type 2 diabetes (T2D) with confirmed metformin use and 143 nondiabetic controls, annotating 614 metabolites.
Tomas Cajka +12 more
wiley +1 more source
The 99th percentile of reference population for cTnI and cTnT assay: Methodology, pathophysiology and clinical implications [PDF]
According to recent international guidelines, including the 2012 Third Universal Definiton of Myocardial Infarction by the Joint ESC/ACCF/AHA/WHF Task Force, an increase in cardiac troponin (cTn) levels over the 99th percentile upper reference limit ...
Clerico, Aldo +6 more
core +1 more source
AbstractThe ST-elevation Myocardial Infarction (STEMI) and Non-ST-elevation Myocardial Infarction (NSTEMI) might occur because of coronary artery stenosis. The gene biomarkers apply to the clinical diagnosis and therapeutic decisions in Myocardial Infarction.
Mohammad Elahimanesh +5 more
openaire +3 more sources
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Prognostic Value of Metabolic Syndrome in Patients With Non-ST Elevated Myocardial Infarction Undergoing Percutaneous Coronary Intervention. [PDF]
Zhao LH +6 more
europepmc +1 more source
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Non-ST-elevation myocardial infarction: dual etiology, twoway therapy
In regularly updated myocardial infarction guidelines, infarctions, including non-ST-elevation myocardial infarction (NSTEMI), were classified into 5 etiological groups, but not all characteristic features of NSTEMI can be explained in all groups ...
Mihály Medvegy, Nóra Medvegy
doaj +1 more source
Cardiovascular involvement in Kawaski Disease [PDF]
This article contains a case report of a 19 month old child with Kawasaki Disease who developed bilateral giant coronary artery aneurysms.peer ...
Chintala, Kavitha +2 more
core
The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD [PDF]
Objective The balance between coronary endothelial dysfunction and repair is influenced by many protective and deleterious factors circulating in the blood.
Ahmed, Nadeem +7 more
core +1 more source

